Taglich Brothers Publishes Updated Coverage Report on Cosmos Health; Maintains Price Target of $4, Nearly 300% Above Current Share Price
Taglich Brothers has published an updated coverage report on Cosmos Health (NASDAQ:COSM), maintaining a Speculative Buy rating with a $4 price target, nearly 300% above the current share price. The report highlights significant growth expectations as Cosmos transitions into a vertically integrated global health organization. Key drivers include increased contract manufacturing at Cana Laboratories and expanded distribution agreements for nutraceutical and disinfectant brands in Europe and the Middle East.
Taglich forecasts FY 2024 revenue at $56.3 million, with a 22.6% increase to $69.0 million in FY 2025, alongside a projected operating profit of $20,000 and cash earnings of $1.6 million. The report suggests that Cosmos Health's valuation should improve with revenue growth and transition to profitability, as its current price-to-sales multiple (0.3X) lags behind the 2.4X sector average.
Taglich Brothers ha pubblicato un rapporto di copertura aggiornato su Cosmos Health (NASDAQ:COSM), mantenendo un rating di Speculative Buy con un target di prezzo di $4, quasi il 300% sopra il prezzo attuale delle azioni. Il rapporto evidenzia significative aspettative di crescita mentre Cosmos si trasforma in un'organizzazione sanitaria globale integrata verticalmente. I principali fattori trainanti includono un aumento della produzione su contratto presso Cana Laboratories e accordi di distribuzione ampliati per marchi di nutraceutici e disinfettanti in Europa e Medio Oriente.
Taglich prevede un fatturato per l'anno fiscale 2024 di $56,3 milioni, con un aumento del 22,6% a $69,0 milioni nell'anno fiscale 2025, insieme a un profitto operativo previsto di $20.000 e guadagni in contante di $1,6 milioni. Il rapporto suggerisce che la valutazione di Cosmos Health dovrebbe migliorare con la crescita dei ricavi e la transizione verso la redditività, poiché il suo attuale multiplo prezzo-fatturato (0,3X) è inferiore alla media settoriale di 2,4X.
Taglich Brothers ha publicado un informe de cobertura actualizado sobre Cosmos Health (NASDAQ:COSM), manteniendo una calificación de Compra Especulativa con un objetivo de precio de $4, casi un 300% por encima del precio actual de la acción. El informe destaca significativas expectativas de crecimiento mientras Cosmos se transforma en una organización de salud global integrada verticalmente. Los principales impulsores incluyen un aumento en la fabricación por contrato en Cana Laboratories y acuerdos de distribución ampliados para marcas de nutracéuticos y desinfectantes en Europa y Medio Oriente.
Taglich pronostica ingresos para el año fiscal 2024 de $56,3 millones, con un aumento del 22,6% a $69,0 millones en el año fiscal 2025, junto con un beneficio operativo proyectado de $20.000 y ganancias en efectivo de $1,6 millones. El informe sugiere que la valoración de Cosmos Health debería mejorar con el crecimiento de los ingresos y la transición a la rentabilidad, ya que su múltiplo precio-ventas actual (0,3X) está por debajo del promedio sectorial de 2,4X.
Taglich Brothers는 Cosmos Health (NASDAQ:COSM)에 대한 업데이트된 분석 보고서를 발표하며 $4의 목표 주가를 유지하고 있으며, 이는 현재 주가보다 거의 300% 높은 수치입니다. 이 보고서는 Cosmos가 수직 통합 글로벌 건강 조직으로 전환하면서 상당한 성장 기대감을 강조합니다. 주요 추진 요소로는 Cana Laboratories에서의 계약 제조 증가 및 유럽과 중동의 건강 보조 식품 및 소독제 브랜드에 대한 유통 계약 확대가 포함됩니다.
Taglich는 2024 회계연도 매출을 $56.3 백만으로 예상하며, 2025 회계연도에는 $69.0 백만으로 22.6% 증가할 것으로 보이고, 운영 이익은 $20,000, 현금 수익은 $1.6 백만으로 예상하고 있습니다. 보고서는 Cosmos Health의 가치 평가가 매출 성장과 수익성 전환에 따라 개선되어야 한다고 제안하며, 현재의 주가 대비 매출 배수(0.3X)는 산업 평균인 2.4X에 비해 뒤처져 있습니다.
Taglich Brothers a publié un rapport de couverture mis à jour sur Cosmos Health (NASDAQ:COSM), maintenant une note d'Achat Spéculatif avec un prix cible de 4 $, presque 300 % au-dessus du prix actuel de l'action. Le rapport met en avant des attentes de croissance significatives alors que Cosmos se transforme en une organisation de santé mondiale intégrée verticalement. Les principaux moteurs comprennent l'augmentation de la fabrication sous contrat chez Cana Laboratories et l'élargissement des accords de distribution pour des marques de nutraceutiques et de désinfectants en Europe et au Moyen-Orient.
Taglich prévoit des revenus pour l'exercice 2024 de 56,3 millions $, avec une augmentation de 22,6 % à 69,0 millions $ pour l'exercice 2025, aux côtés d'un bénéfice d'exploitation projeté de 20 000 $ et de bénéfices en espèces de 1,6 million $. Le rapport suggère que l'évaluation de Cosmos Health devrait s'améliorer avec la croissance des revenus et le passage à la rentabilité, alors que son multiple prix/vente actuel (0,3X) est en retard par rapport à la moyenne sectorielle de 2,4X.
Taglich Brothers hat einen aktualisierten Berichterstattungsbericht über Cosmos Health (NASDAQ:COSM) veröffentlicht und eine Spekulative Kaufen-Einstufung mit einem Preisziel von $4 beibehalten, was fast 300% über dem aktuellen Kurs liegt. Der Bericht hebt deutliche Wachstumserwartungen hervor, während Cosmos sich in eine vertikal integrierte globale Gesundheitsorganisation verwandelt. Zu den Hauptfaktoren gehören die erhöhte Vertragsproduktion bei Cana Laboratories und erweiterte Vertriebsvereinbarungen für Nutraceutical- und Desinfektionsmarken in Europa und dem Nahen Osten.
Taglich prognostiziert für das Geschäftsjahr 2024 Einnahmen von $56,3 Millionen, mit einem Anstieg um 22,6% auf $69,0 Millionen im Geschäftsjahr 2025, sowie einen prognostizierten Betriebsgewinn von $20.000 und einen Cash-Ertrag von $1,6 Millionen. Der Bericht legt nahe, dass die Bewertung von Cosmos Health mit dem Umsatzwachstum und dem Übergang zur Rentabilität verbessert werden sollte, da das aktuelle Kurs-Umsatz-Verhältnis (0,3X) hinter dem Branchenmittelwert von 2,4X zurückbleibt.
- Taglich Brothers maintains a $4 price target, implying a nearly 300% potential increase in share price
- FY 2024 revenue forecast of $56.3 million, with a 22.6% increase to $69.0 million in FY 2025
- Projected operating profit of $20,000 and cash earnings of $1.6 million for FY 2025
- Expansion of contract manufacturing at Cana Laboratories and distribution agreements for proprietary brands
- Analyst expectation of Cosmos becoming cash flow positive in 2025
- Current price-to-sales multiple (0.3X) significantly lags behind the 2.4X sector average
- Execution risks and potential warrant dilution factored into the price target
- Minimal operating profit projection of $20,000 for FY 2025
Insights
The updated coverage report from Taglich Brothers highlights Cosmos Health's potential for significant growth, but investors should approach this analysis with caution. The
While the forecast of
The valuation argument relies heavily on multiple expansion from 0.3X to 1.4X price-to-sales, which may be optimistic given the current market conditions and the company's financial performance. Investors should carefully consider the execution risks and potential dilution mentioned in the report before making investment decisions based on this price target.
Cosmos Health's transition into a vertically integrated global health organization presents both opportunities and challenges. The company's strategy to leverage Cana Laboratories for contract manufacturing and expand distribution of its nutraceutical and disinfectant brands in Europe and the Middle East could drive growth. However, these markets are highly competitive and regulated.
The projected revenue growth from
Investors should monitor key performance indicators such as market penetration rates, customer acquisition costs and regulatory approvals in new markets. The success of Cosmos Health's expansion strategy will heavily depend on these factors, which are not fully addressed in the coverage report.
CHICAGO, IL / ACCESSWIRE / September 17, 2024 / Cosmos Health Inc. ("Cosmos Health" or the "Company'') (NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today that on September 16, 2024, Taglich Brothers, Inc. ("Taglich Brothers") published its updated research report on the Company's common stock.
Key highlights of Taglich Brothers' updated coverage report include:
Maintains Speculative Buy rating with a
$4 price target, implying a nearly four-fold share price increase over the next 12 months.Significant growth is expected as the Company transitions into a vertically integrated global health organization, driven by increased contract manufacturing at Cana Laboratories and expanded distribution agreements for its nutraceutical and disinfectant brands in Europe and the Middle East.
FY 2024 revenue is forecasted at
$56.3 million , with a22.6% increase to$69.0 million in FY 2025, alongside a projected operating profit of$20,000 and cash earnings of$1.6 million .Valuation should improve with revenue growth, transitioning to operating profit and positive cash earnings, as Cosmos Health's price-to-sales multiple (0.3X) lags behind the 2.4X sector average for similar companies in medical distribution and drug manufacturing.
Investors are likely to assign a valuation multiple closer to industry standards. Applying a 1.4X price-to-sales multiple to the 2025 sales per share forecast of
$3.86 supports the$4 price target, factoring in execution risks and potential warrant dilution.
Greg Siokas, CEO of Cosmos Health, stated: "I am pleased that Taglich Brothers has reaffirmed its price target of
About Cosmos Health Inc.
Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe® and C-Sept®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, as well as LinkedIn and X.
Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could", are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, the impact of the COVID-19 pandemic and the war in Ukraine, on the Company's business, operations and the economy in general, and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward- looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Disclaimer
All research issued by Taglich Brothers is based on public information. The Company does not undertake the responsibility to advise you of changes in figures or in their views. The Company pays a fee of
Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com
+44 207 0971 653
SOURCE: Cosmos Health Inc.
View the original press release on accesswire.com
FAQ
What is Taglich Brothers' price target for Cosmos Health (COSM) stock?
What is the revenue forecast for Cosmos Health (COSM) in FY 2024 and FY 2025?
When is Cosmos Health (COSM) expected to become cash flow positive according to the Taglich Brothers report?
What are the main growth drivers for Cosmos Health (COSM) mentioned in the Taglich Brothers report?
